Ares Capital Co. (NASDAQ:ARCC – Get Free Report) shares hit a new 52-week high on Monday after JPMorgan Chase & Co. raised their price target on the stock from $23.00 to $24.50. JPMorgan Chase & Co. currently has an overweight rating on the stock. Ares Capital traded as high as $23.77 and last traded at $23.76, with a volume of 3786340 shares trading hands. The stock had previously closed at $23.67.
A number of other analysts have also weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Ares Capital from $23.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. B. Riley lifted their price objective on shares of Ares Capital from $21.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded Ares Capital from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.79.
Check Out Our Latest Stock Report on Ares Capital
Institutional Inflows and Outflows
Ares Capital Trading Up 0.4 %
The company has a 50 day moving average of $22.28 and a 200-day moving average of $21.45. The stock has a market cap of $15.35 billion, a price-to-earnings ratio of 9.14 and a beta of 1.01. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.29 and a current ratio of 1.29.
Ares Capital Company Profile
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors.
See Also
- Five stocks we like better than Ares Capital
- Comparing and Trading High PE Ratio Stocks
- How to Invest in Small Cap Stocks
- 3 Healthcare Dividend Stocks to Buy
- These Are the Dividend Stocks Insiders Bought in January
- What is a Dividend King?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Ares Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ares Capital and related companies with MarketBeat.com's FREE daily email newsletter.